US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Vyome Holdings, Inc.

2.25

-0.0300-1.32%

Post-market: 2.250.00000.00%16:10 EDT

Volume:5K

Turnover:10.66K

Market Cap:15.79M

PE:-1.40

High:2.30

Open:2.21

Low:2.21

Close:2.28

52wk High:12.00

52wk Low:1.75

Shares:7.02M

Float Shares:1.54M

Volume Ratio:0.38

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6111

EPS(LYR):-4.7480

ROE:-999.17%

ROA:-48.79%

PB:2.61

PE(LYR):-0.47

Loading ...

Overview Company News Filings

Vyome Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Vyome Net Loss Widens to $719,683 in Q2 FY26; Revenue Falls to $26,955

Vyome Holdings Inc Expected to Post a Loss of 19 Cents a Share - Earnings Preview

Vyome announces CNIPA granted patent covering formula related to besifloxacin

Vyome Wins China Patent for Besifloxacin Gel in Inflammatory Acne

Vyome Granted Chinese Patent Strengthening Immuno-inflammation Portfolio

THOMSON REUTERS

Vyome net loss widens to $985,521 in Q1 FY26

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

THOMSON REUTERS

Vyome - Q1 2026 Net Loss Attributable to Common Shareholders $963,000 or $0.15 per Share

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Vyome Holdings (HIND)

Vyome Holdings Q1 FY26 net loss widens to $985,521; revenue drops to $31,591

Vyome signs exclusive license agreement with Impetis

Vyome signs exclusive licensing deal with Impetis for selective JAK inhibitors

Vyome Holdings Inc - Receives Exclusive License for Selective Jak 1/3 and Jak1 Inhibitors

THOMSON REUTERS

Vyome Strikes Deal With Impetis Biosciences, Opening a ~$57B Market Opportunity

THOMSON REUTERS

Vyome initiated with a Buy at Litchfield Hills

Vyome Holdings shareholders approve cut in authorized common shares to 50 million

Vyome Holdings presents Phase 2 study results on VT-1953

Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR

Vyome presents Phase 2 VT-1953 data for malignant fungating wounds at AACR 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/HIND/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HIND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","market":"US","secType":"STK","nameCN":"Vyome Holdings, Inc.","latestPrice":2.25,"timestamp":1787342400000,"preClose":2.28,"halted":0,"volume":4688,"hourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.25,"latestTime":"16:10 EDT","volume":6,"amount":13.68,"timestamp":1787343004180,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.013157894736842021,"floatShares":1543899,"shares":7018528,"eps":-1.611126,"marketStatus":"Market Closed","change":-0.03,"latestTime":"08-21 16:00:00 EDT","open":2.21,"high":2.3,"low":2.21,"amount":10660,"amplitude":0.039474,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.611126,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1475726400000,"exchange":"NASDAQ","adjPreClose":2.28,"postHourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.25,"latestTime":"16:10 EDT","volume":6,"amount":13.68,"timestamp":1787343004180,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3774678757928943},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","floatShares":1543899,"roa":"-48.79%","roe":"-999.17%","lyrEps":-4.747979,"volumeRatio":0.3774678757928943,"shares":7018528,"dividePrice":0,"high":2.3,"amplitude":0.039474,"preClose":2.28,"low":2.21,"week52Low":1.75,"pbRate":"2.61","psRate":"121.73","week52High":12,"institutionHeld":0,"latestPrice":2.25,"eps":-1.611126,"divideRate":0,"volume":4688,"delay":0,"ttmEps":-1.611126,"open":2.21,"prevYearClose":3.44,"prevWeekClose":2.18,"prevMonthClose":2.115,"prevQuarterClose":2.15,"fiveDayClose":2.18,"twentyDayClose":2.06,"sixtyDayClose":2.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIND\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"HIND","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2026-06-03","symbol":"HIND","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1780459200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2026-05-12","symbol":"HIND","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2026-03-18","symbol":"HIND","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773806400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-14","symbol":"HIND","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-3.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIND\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1777953600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HIND\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HIND","date":"2026-08-21","current":-1.396539,"percent":0.712,"low":-23.816091,"twenty":-11.259279,"median":-1.558668,"eighty":-1.38689,"high":-0.001601,"avg":-5.443771,"sd":7.427755,"marketCap":16002243},"quantilePoints":[{"date":"2025-08-22","current":-12.854344,"twenty":-12.392244,"median":-11.699095,"eighty":-11.005946,"marketCap":20748595},{"date":"2025-08-29","current":-11.259279,"twenty":-13.22027,"median":-12.854344,"eighty":-11.500884,"marketCap":18173952},{"date":"2025-09-05","current":-9.124707,"twenty":-13.182739,"median":-11.259279,"eighty":-10.03366,"marketCap":14728473},{"date":"2025-09-12","current":-0.001997,"twenty":-12.854344,"median":-10.288753,"eighty":-0.00213,"marketCap":2910},{"date":"2025-09-19","current":-0.001751,"twenty":-12.467306,"median":-9.124707,"eighty":-0.001933,"marketCap":2551},{"date":"2025-09-26","current":-20.664803,"twenty":-13.499407,"median":-10.288753,"eighty":-0.001997,"marketCap":30109879},{"date":"2025-10-03","current":-20.473816,"twenty":-20.473816,"median":-11.259279,"eighty":-0.002098,"marketCap":29831599},{"date":"2025-10-10","current":-21.00858,"twenty":-21.00858,"median":-13.018541,"eighty":-0.002106,"marketCap":30610783},{"date":"2025-10-17","current":-19.327894,"twenty":-20.855791,"median":-13.499407,"eighty":-0.00213,"marketCap":28161920},{"date":"2025-10-24","current":-20.850495,"twenty":-20.850495,"median":-19.346992,"eighty":-0.002143,"marketCap":30380443},{"date":"2025-10-31","current":-21.039016,"twenty":-20.850495,"median":-19.786263,"eighty":-9.124707,"marketCap":30655130},{"date":"2025-11-07","current":-21.340651,"twenty":-21.039016,"median":-20.206435,"eighty":-10.010203,"marketCap":31094630},{"date":"2025-11-14","current":-18.588235,"twenty":-21.00858,"median":-20.168237,"eighty":-10.03366,"marketCap":27084192},{"date":"2025-11-21","current":-17.984966,"twenty":-21.00858,"median":-20.037322,"eighty":-10.543846,"marketCap":26205192},{"date":"2025-11-28","current":-3.129419,"twenty":-20.886349,"median":-19.767164,"eighty":-7.929274,"marketCap":29238478},{"date":"2025-12-05","current":-3.075047,"twenty":-20.851554,"median":-19.327894,"eighty":-3.104045,"marketCap":28730474},{"date":"2025-12-12","current":-2.881724,"twenty":-20.850495,"median":-18.663643,"eighty":-3.026716,"marketCap":26924236},{"date":"2025-12-19","current":-2.342231,"twenty":-20.820331,"median":-18.362009,"eighty":-2.975968,"marketCap":21883703},{"date":"2025-12-26","current":-2.271547,"twenty":-20.790168,"median":-17.381696,"eighty":-2.665444,"marketCap":21223297},{"date":"2026-01-02","current":-2.078224,"twenty":-20.744922,"median":-13.229653,"eighty":-2.363376,"marketCap":19417059},{"date":"2026-01-09","current":-2.072183,"twenty":-20.685727,"median":-12.660825,"eighty":-2.260673,"marketCap":19360614},{"date":"2026-01-16","current":-1.866777,"twenty":-20.618426,"median":-10.790143,"eighty":-2.104806,"marketCap":17441486},{"date":"2026-01-23","current":-1.761053,"twenty":-20.541319,"median":-10.03366,"eighty":-2.062517,"marketCap":16453700},{"date":"2026-01-30","current":-1.292849,"twenty":-20.511156,"median":-6.2932,"eighty":-1.940481,"marketCap":12079217},{"date":"2026-02-06","current":-1.38951,"twenty":-20.503688,"median":-3.129419,"eighty":-1.87886,"marketCap":12982336},{"date":"2026-02-13","current":-1.576792,"twenty":-20.469996,"median":-3.093171,"eighty":-1.729639,"marketCap":14732129},{"date":"2026-02-20","current":-1.661371,"twenty":-20.454717,"median":-3.029737,"eighty":-1.661371,"marketCap":15522358},{"date":"2026-02-27","current":-2.029893,"twenty":-20.435747,"median":-3.008592,"eighty":-1.661371,"marketCap":18965499},{"date":"2026-03-06","current":-1.758033,"twenty":-20.359224,"median":-2.95875,"eighty":-1.667412,"marketCap":16425477},{"date":"2026-03-13","current":-1.4318,"twenty":-20.28493,"median":-2.791104,"eighty":-1.619082,"marketCap":13377450},{"date":"2026-03-20","current":-1.254087,"twenty":-20.244632,"median":-2.425601,"eighty":-1.576792,"marketCap":12869446},{"date":"2026-03-27","current":-1.504653,"twenty":-20.168237,"median":-2.342231,"eighty":-1.56471,"marketCap":15440761},{"date":"2026-04-02","current":-1.470457,"twenty":-20.080611,"median":-2.271547,"eighty":-1.552627,"marketCap":15089835},{"date":"2026-04-10","current":-1.573046,"twenty":-20.054657,"median":-2.19603,"eighty":-1.544169,"marketCap":16142614},{"date":"2026-04-17","current":-1.518332,"twenty":-20.027528,"median":-2.096348,"eighty":-1.529274,"marketCap":15581132},{"date":"2026-04-24","current":-1.545689,"twenty":-19.83321,"median":-2.075203,"eighty":-1.529274,"marketCap":15861873},{"date":"2026-05-01","current":-1.388384,"twenty":-19.755705,"median":-2.0601,"eighty":-1.503285,"marketCap":14247611},{"date":"2026-05-08","current":-1.43626,"twenty":-19.442486,"median":-1.999686,"eighty":-1.470457,"marketCap":14738908},{"date":"2026-05-15","current":-1.232791,"twenty":-19.335533,"median":-1.945315,"eighty":-1.456778,"marketCap":13475573},{"date":"2026-05-22","current":-1.431836,"twenty":-19.175104,"median":-1.918128,"eighty":-1.435375,"marketCap":15651317},{"date":"2026-05-29","current":-1.508885,"twenty":-18.898194,"median":-1.893963,"eighty":-1.43449,"marketCap":16493540},{"date":"2026-06-05","current":-1.476781,"twenty":-18.648562,"median":-1.87886,"eighty":-1.43626,"marketCap":16142614},{"date":"2026-06-12","current":-1.46394,"twenty":-18.475122,"median":-1.845633,"eighty":-1.431822,"marketCap":16002243},{"date":"2026-06-18","current":-1.399732,"twenty":-18.384631,"median":-1.759543,"eighty":-1.421213,"marketCap":15300391},{"date":"2026-06-26","current":-1.354786,"twenty":-18.211192,"median":-1.721785,"eighty":-1.4023,"marketCap":14809094},{"date":"2026-07-02","current":-1.444678,"twenty":-17.864312,"median":-1.691578,"eighty":-1.395484,"marketCap":15791688},{"date":"2026-07-10","current":-1.431836,"twenty":-16.605238,"median":-1.658351,"eighty":-1.395484,"marketCap":15651317},{"date":"2026-07-17","current":-1.406153,"twenty":-13.445456,"median":-1.607243,"eighty":-1.397164,"marketCap":15370576},{"date":"2026-07-24","current":-1.374049,"twenty":-13.22027,"median":-1.588875,"eighty":-1.395224,"marketCap":15019649},{"date":"2026-07-31","current":-1.290579,"twenty":-13.182739,"median":-1.586725,"eighty":-1.393311,"marketCap":14107241},{"date":"2026-08-07","current":-1.374049,"twenty":-12.854344,"median":-1.573046,"eighty":-1.388384,"marketCap":15019649},{"date":"2026-08-14","current":-1.340677,"twenty":-12.467306,"median":-1.565459,"eighty":-1.38689,"marketCap":15160020},{"date":"2026-08-21","current":-1.415158,"twenty":-11.259279,"median":-1.558668,"eighty":-1.38689,"marketCap":16002243}],"updateTime":1787524553841},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIND\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659958185","title":"Vyome Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659958185","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659958185?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:46","pubTimestamp":1786571203,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc reports results for the quarter ended June 30 - Earnings SummaryVyome Holdings IncHIND.OQreported a quarterly adjusted loss of 10 cents per share for the quarter ended June 30.  The","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N44929T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HIND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659818880","title":"Vyome Net Loss Widens to $719,683 in Q2 FY26; Revenue Falls to $26,955","url":"https://stock-news.laohu8.com/highlight/detail?id=2659818880","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659818880?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:33","pubTimestamp":1786566826,"startTime":"0","endTime":"0","summary":"Vyome net loss widens to $719,683 in Q2 FY26; revenue falls to $26,955Vyome Holdings posted a net loss of $719,683 for the three months ended June 30, 2026, widening from $308,760 a year earlier.Reven","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL9ywcM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300485","BK0028","HIND","BK0046","BK0239","BK4007","BK0012","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995167","title":"Vyome Holdings Inc Expected to Post a Loss of 19 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995167","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658995167?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:32","pubTimestamp":1786393926,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc <HIND.OQ> expected to post a loss of19cents a share - Earnings PreviewVyome Holdings IncHIND.OQHIND.Ois expected to  report resultson August 12  for the period ending June 30 2026LSEG's mean analyst estimate for Vyome Holdings Inc is for a loss of 19 cents per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Vyome Holdings Inc is $11.50, about 432.4% above its last closing price of $2.16This summary was machine generated August 10 at 20:32 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4471WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","HIND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648548296","title":"Vyome announces CNIPA granted patent covering formula related to besifloxacin","url":"https://stock-news.laohu8.com/highlight/detail?id=2648548296","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648548296?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:10","pubTimestamp":1782907837,"startTime":"0","endTime":"0","summary":"Vyome (HIND) announces that the China National Intellectual Property Administration, CNIPA, has granted a patent covering formulation and therapeut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-announces-cnipa-granted-patent-covering-formula-related-to-besifloxacin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-announces-cnipa-granted-patent-covering-formula-related-to-besifloxacin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648548824","title":"Vyome Wins China Patent for Besifloxacin Gel in Inflammatory Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2648548824","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648548824?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:02","pubTimestamp":1782907350,"startTime":"0","endTime":"0","summary":"Vyome wins China patent for besifloxacin gel in inflammatory acneVyome Holdings received a Chinese patent covering formulation and therapeutic-use claims for its besifloxacin topical gel program in in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL1N18xL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648654886","title":"Vyome Granted Chinese Patent Strengthening Immuno-inflammation Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2648654886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648654886?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:02","pubTimestamp":1782907333,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nFWN4330KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638169698","title":"Vyome net loss widens to $985,521 in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2638169698","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638169698?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:03","pubTimestamp":1779969828,"startTime":"0","endTime":"0","summary":"Vyome Holdings posted a net loss attributable to common shareholders of $963,000, or $0.15 per share, for Q1 ended March 31, 2026.Revenue fell to $31,591 from $198,581 a year earlier, while operating expenses jumped to $1.1 million from $353,417.Cash and cash equivalents climbed to $8.8 million from $5 million at Dec. 31, 2025, following a $5.29 million common-share sale.VT-1953 advanced toward pivotal-stage readiness with FDA discussions; an Orphan Drug Designation application was filed for malignant fungating wounds.Management highlighted a debt-free capital structure; VT-1953 Phase 2 data were presented at AACR 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1HnTSd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4082","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638986286","title":"Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2638986286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638986286?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA5JWQCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","HIND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698401","title":"Vyome - Q1 2026 Net Loss Attributable to Common Shareholders $963,000 or $0.15 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698401?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA5JWQCX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636829826","title":"Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Vyome Holdings (HIND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636829826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636829826?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:30","pubTimestamp":1779291009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medtronic (MDT) and Vyome Holdings (HIND) with bulli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-vyome-holdings-hind-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-medtronic-mdt-vyome-holdings-hind-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4112","BK4007","LU0006306889.USD","LU0162691827.USD","LU0211326839.USD","MDT","LU0128526141.USD","IE00BVYPNV92.GBP","LU2028103732.USD","IE00BFXG1179.USD","LU0432979614.USD","LU1989764664.SGD","XBI","BK4533","BLSX","IE00BGHQF631.EUR","BK4137","IE00B3T34201.USD","LU1061106388.HKD","LU1983299246.USD","LU2089984988.USD","BK4566","LU0158827948.USD","IE00BVYPNW00.USD","IE000M9KFDE8.USD","LU0314106906.USD","LU1116320737.USD","IE00B42XCP33.USD","IE00BQXX3D17.EUR","LU1291159041.SGD","LABU","LU0211331839.USD","LU0265550359.USD","LU1571399168.USD","LU2089283258.USD","LU0070302665.USD","LU0208291251.USD","LU2468319806.SGD","LU0976567544.SGD","LU0496365809.HKD","LU1023059063.AUD","LU1057294990.SGD","BK4581","LU1244550221.USD","LU1244550577.SGD","BLSG","LU2111349929.HKD","IE00B3PB1722.GBP","LU0122379950.USD","LU0158827781.USD","LU2271345857.HKD","LU0265550946.USD","LU1989771016.USD","BK4585","IE00BQXX3F31.USD","LU1989764748.USD","LU2023251221.USD","BK4588","LU2089284900.SGD","LU0106261372.USD","BK4082","IE00BQXX3C00.GBP","LU0211326755.USD","LU1116320901.HKD","LU0320765489.SGD","LU1244550494.USD","IE00BDGV0183.EUR","LU1506573853.SGD","LU2112291526.USD","HIND","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635124209","title":"Vyome Holdings Q1 FY26 net loss widens to $985,521; revenue drops to $31,591","url":"https://stock-news.laohu8.com/highlight/detail?id=2635124209","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635124209?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:04","pubTimestamp":1778616259,"startTime":"0","endTime":"0","summary":"Vyome Holdings posted a net loss of $985,521 for the three months ended March 31, 2026, widening from $293,974 a year earlier.Revenue fell 84.09% to $31,591, while operating loss widened to $1.13 million from $198,998.Research and development expense climbed to $666,405 from $90,268, due to scaling up regulatory consulting and CMC preparation work for VT-1953.Selling, general and administrative expense rose to $477,575 from $259,626 on higher legal, accounting and auditing fees tied to the merger, with stock-based compensation of $5,696.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL92XcSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635246500","title":"Vyome signs exclusive license agreement with Impetis","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246500","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246500?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:18","pubTimestamp":1778602702,"startTime":"0","endTime":"0","summary":"Vyome (HIND) Holdings announced the signing of an agreement with Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-signs-exclusive-license-agreement-with-impetis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-signs-exclusive-license-agreement-with-impetis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","HIND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021622","title":"Vyome signs exclusive licensing deal with Impetis for selective JAK inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021622","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634021622?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:02","pubTimestamp":1778587342,"startTime":"0","endTime":"0","summary":"Vyome signed exclusive licensing agreement with Impetis Biosciences, TATA Enterprise, covering a selective JAK 1/3 inhibitor plus a selective JAK1 inhibitor for development and commercialization.Deal expands pipeline beyond lead program VT-1953, positioning company to enter broader immuno-inflammatory indications.JAK inhibitors market projected to reach USD 56.78 billion by 2030, up from USD 23.56 billion in 2025.Consideration structured to be tied to commercialization, with any future development planned through non-dilutive pathways.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire  on May 12, 2026, and is solely responsible for the in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL1dl0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216409","title":"Vyome Holdings Inc - Receives Exclusive License for Selective Jak 1/3 and Jak1 Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216409?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P0TI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216123","title":"Vyome Strikes Deal With Impetis Biosciences, Opening a ~$57B Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216123?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587247,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P0TI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930760","title":"Vyome initiated with a Buy at Litchfield Hills","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930760?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:39","pubTimestamp":1777894774,"startTime":"0","endTime":"0","summary":"Litchfield Hills analyst Theodore O’Neill initiated coverage of Vyome (HIND) with a Buy rating and $8 price target The company’s drug development o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-initiated-with-a-buy-at-litchfield-hills-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-initiated-with-a-buy-at-litchfield-hills-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631524806","title":"Vyome Holdings shareholders approve cut in authorized common shares to 50 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631524806","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631524806?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:01","pubTimestamp":1777496509,"startTime":"0","endTime":"0","summary":"Vyome Holdings held its annual shareholder meeting on April 24, 2026.Stockholders adopted an amendment to certificate of incorporation cutting authorized common shares to 50,000,000 from 300,000,000.Company filed a tenth amendment to its certificate of incorporation on April 24, 2026, executing the authorized-share reduction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6zfqlH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629492860","title":"Vyome Holdings presents Phase 2 study results on VT-1953","url":"https://stock-news.laohu8.com/highlight/detail?id=2629492860","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629492860?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:37","pubTimestamp":1776861443,"startTime":"0","endTime":"0","summary":"Vyome Holdings (HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-holdings-presents-phase-2-study-results-on-vt-1953-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-holdings-presents-phase-2-study-results-on-vt-1953-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HIND","BK4585","BK4007","BK4082","VT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629045062","title":"Vyome presents Phase 2 data for VT-1953 in malignant fungating wounds at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2629045062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629045062?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:03","pubTimestamp":1776859438,"startTime":"0","endTime":"0","summary":"Vyome presented full Phase 2 investigator-initiated study results for VT-1953 at AACR 2026 on April 21, 2026.VT-1953 showed clinically meaningful improvement in malignant fungating wound malodor versus vehicle control.Patient-reported quality of life improved on malodor impact measures, with pain also easing; exudate levels did not change.No treatment-associated adverse effects were reported in study.Vyome plans to advance VT-1953 into registrational studies, citing third-party estimates of USD 2.2 billion total addressable U.S. market for malignant fungating wound symptom treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire  on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6JV8Kk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","HIND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625545679","title":"Vyome presents Phase 2 VT-1953 data for malignant fungating wounds at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625545679","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625545679?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:00","pubTimestamp":1775476846,"startTime":"0","endTime":"0","summary":"Vyome set presentation of full Phase 2 results for VT-1953 topical gel in malignant fungating wounds at AACR Annual Meeting on April 21, 2026.Study readout showed VT-1953 outperformed vehicle in efficacy, with safety profile supporting advancement to pivotal studies.Management guided FDA interactions in Q2 2026 to align on pivotal trial design.Third-party analysts estimated total addressable US market at USD 2.2 billion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL5mjnZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","HIND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}